Massive flu drug showdown: 3,000 volunteers needed to find best antiviral

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study * Adults, male or female, aged 18 to 60 years at time of consent. * Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours) * Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of \<30 * Able to walk unaided and unimpeded in activities of daily living (ADLs) * Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits Exclusion Criteria: The patient may not enter the study if ANY of the following apply: * Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity * Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity * BMI ≥35 Kg/m2 * Clinically relevant laboratory abnormalities discovered at screening * Haemoglobin \<10g/dL * Platelet count \<100,000/uL * ALT \> 2x ULN * Total bilirubin \>1.5 x ULN * eGFR \<70mls/min/1.73m2 * For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join) * Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics * Currently participating in another interventional influenza or COVID-19 therapeutic trial * Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required) * Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR) * Received live attenuated influenza virus vaccine within 3 weeks prior to study entry